Drug Type Small molecule drug |
Synonyms BCQB, Bencycloquidium Bromide Nasal Spray + [1] |
Mechanism M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (17 Mar 2020), |
RegulationSpecial Review Project (CN), Priority Review (CN) |
Molecular FormulaC21H32BrNO2 |
InChIKeyLMUJEWVKOCYOQL-UHFFFAOYSA-M |
CAS Registry860804-18-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic | CN | 17 Mar 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Common Cold | Phase 3 | CN | 28 Sep 2021 | |
Nasal Obstruction | Phase 3 | CN | 28 Sep 2021 | |
Sneezing | Phase 3 | CN | 28 Sep 2021 | |
Rhinitis, Allergic | Phase 1 | CN | 12 Jan 2016 | |
Rhinitis, Allergic | Phase 1 | CN | 12 Jan 2016 | |
Pulmonary Disease, Chronic Obstructive | Phase 1 | CN | 09 Sep 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 1 | CN | 09 Sep 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 1 | CN | 09 Sep 2015 | |
Rhinitis, Allergic, Perennial | Discovery | CN | 12 Aug 2016 |